Products Affected - Description
Leuprolide 1 mg/0.2 mL Injection, Teva
2.8 mL multiple-dose vial with 14-day kit (NDC 00703-4014-18)
Reason for the Shortage
- Sandoz states the shortage was due to increased demand.
- Sandoz relaunched Leuprolide 1 mg/0.2 mL 2.8 mL injection in late-January, 2013. The product has a new NDC number.
- Teva states the shortage is due to manufacturing delays.
Leuprolide 1 mg/0.2 mL Injection, Caraco
2.8 mL multiple-dose vial with 14-day kit (NDC 41616-0936-40)
Leuprolide 1 mg/0.2 mL Injection, Sandoz
2.8 mL multiple-dose vial with 14-day kit (NDC 00781-4003-32)
Estimated Resupply Dates
Teva has leuprolide acetate injection on back order and the company estimates a release date in the second quarter of 2015.
September 11, 2014; June 23, 2014; April 15, 2014; February 14, 2014; January 15, 2014; October 15, 2013; September 26, 2013; July 16, 2013; May 15, 2013; March 22, 2013; February 7, 2013; January 9, 2013; November 12, 2012; August 13, 2012; June 21, 2012; April 20, 2012; March 2, 2012; February 3, 2012; December 28, 2011; December 1, 2011; October 27, 2011; August 19, 2011; July 22, 2011; June 24, 2011; June 3, 2011; May 5, 2011; March 24, 2011; February 25, 2011, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins